Adcytherix Doses First Patient in Phase 1 Trial of ADCX-020, Marking Transition to Clinical-Stage Company
核心洞察
Adcytherix (搜索) has dosed the first patient in its Phase 1 clinical trial of ADCX-020 (搜索), marking the company's transition to clinical-stage operations within its second year of existence.
The open-label study will evaluate safety, pharmacokinetics, and preliminary anti-tumor activity of ADCX-020 (搜索) in patients with advanced solid tumors (搜索) through dose-escalation and cohort expansion phases.
ADCX-020 (搜索) incorporates a stable linker with an exatecan-derived topoisomerase I (搜索) inhibitor, designed to address limitations of earlier ADC products through optimized molecular design.
Adcytherix (搜索), a French biopharmaceutical company developing next-generation antibody-drug conjugates (ADCs), has achieved a significant milestone by dosing the first patient in the Phase 1 clinical trial of ADCX-020 (搜索), its most advanced product candidate. This achievement marks the company's transition to clinical-stage operations less than two years after its inception.
Clinical Trial Design and Objectives
The Phase 1a/b trial is an open-label study designed to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of ADCX-020 (搜索) in patients with advanced solid tumors (搜索). The study includes a dose-escalation phase followed by dose-optimization and selected cohort expansion in patients with relapsed or refractory diseases.
"Our Phase 1a/b study is designed to characterize its safety and pharmacokinetic profile while generating the data required to advance development, with the ultimate goal of delivering meaningful new treatment options for patients with high unmet need," said Jan Schellens, Chief Medical Officer of Adcytherix (搜索).
Innovative ADC Design
ADCX-020 (搜索) has been engineered to address key limitations of earlier ADC products through an optimized molecular design. The compound incorporates a stable linker combined with an exatecan-derived topoisomerase I (搜索) inhibitor, a clinically validated payload class designed to support an improved therapeutic index and broader applicability across multiple tumor types.
The drug candidate represents the first clinical validation of Adcytherix (搜索)'s ADCX Engine platform, which combines clinically validated targets with innovative payloads derived from approved cancer (搜索) treatments. This approach aims to deliver differentiated, de-risked therapies driven by patient need.
Leadership Expansion
Concurrent with the clinical milestone, Adcytherix (搜索) has significantly strengthened its leadership team with three key appointments. Paul Jackson has joined as Chief Operating Officer, bringing deep expertise in ADC technologies, development strategy, and operational scale-up. As an experienced biotech entrepreneur, Jackson has built and led innovative payload platforms and structured development programs from preclinical stages through clinical readiness.
Magali Gibou has been appointed Chief Regulatory & Quality Officer, contributing extensive experience in global regulatory strategy and quality systems for innovative biopharmaceutical products. She has supported multiple programs through key regulatory interactions and clinical-stage transitions.
Simon Sturge has been named Independent Chairman of the Board, bringing more than four decades of international leadership experience across biotechnology and pharmaceuticals, including senior executive roles, CEO positions, and board chairmanships at leading life sciences companies.
Strategic Positioning and Pipeline Development
"Administering ADCX-020 (搜索) to the first patient is a defining milestone for Adcytherix (搜索)," said Jack Elands, Founder and Chief Executive Officer. "It reflects our ability to translate strong scientific vision into a clinical program and confirms our readiness to operate as a clinical-stage company."
The company is advancing several additional programs targeting clinically validated antigens and leveraging payloads with novel mechanisms of action, selected from approved cancer (搜索) treatments. This strategy supports Adcytherix (搜索)'s ambition to build a diversified ADC franchise across multiple clinically validated targets and payload classes to address a broad range of oncology indications.
Financial Foundation and Future Outlook
With a solid financial foundation following its €105 million Series A financing, Adcytherix (搜索) is positioned to advance ADCX-020 (搜索) through clinical development while building its differentiated ADC franchise. The company's disciplined execution and capital-efficient development model have enabled this rapid progression from inception to clinical-stage operations.
The company's ambition is to become a global leader in next-generation ADC therapeutics, leveraging its ADCX Engine platform to develop novel treatments for cancer (搜索) and other serious diseases with high unmet medical need.